FDA Approves Ipsen’s Palovarotene for Ultra-Rare Bone Disease

The FDA on Wednesday approved Ipsen’s palovarotene, now to be sold under the brand name Sohonos, for the treatment of fibrodysplasia ossificans progressiva.